Unfortunately the results of this trial have been clearly disappointing regarding outcome, and marizomib-related neurological and psychiatric toxicities were quite significant. 83 IDH1 and IDH2 mutations are present in about 10% of GBs diagnosed according to the WHO 2016 classification, 84 but these tumors are now classified as grade 4 astrocytoma 85 and have a better prognosis even in the recurrent setting. 86 Nevertheless, due to the importance of this alteration in gliomas, research on targeting IDH is continuing while the new classification is adopted for pathological diagnosis. 63 , 87 Several early-phase studies targeting IDH are ongoing; most include low-grade gliomas but not all of them limit inclusion to this grade.
← all excerpts
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.
1
—
—